JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial

  • 0Vascular Medicine Program, Department of Medicine, University of California San Diego, 9500 Gilman Dr, BSB 1080, La Jolla, CA 92093-0682, USA. stsimikas@ucsd.edu
Circulation +

|

September 9, 2004

|

September 9, 2004

Related Experiment Videos

Contact us if these videos are not relevant.

View abstract on PubMed

Summary

This summary is machine-generated.

Atorvastatin treatment reduced oxidized phospholipids (OxPL) on all apoB-100 particles in acute coronary syndrome patients. This suggests atorvastatin may help clear proinflammatory OxPL, potentially reducing ischemic events.

Area Of Science

  • Cardiovascular Medicine
  • Atherosclerosis Research
  • Pharmacology

Background

  • Oxidized phospholipids (OxPL) are key components of atherosclerotic plaques.
  • Lipoprotein (a) [Lp(a)] in plasma binds to OxPL.
  • Oxidized low-density lipoprotein (OxLDL) plays a role in atherosclerosis.

Purpose Of The Study

  • To evaluate the impact of atorvastatin on OxLDL in patients with acute coronary syndromes (ACS).
  • To investigate the relationship between OxPL, apoB-100, and Lp(a) levels following atorvastatin treatment.

Main Methods

  • A randomized, placebo-controlled study involving 2341 ACS patients.
  • Measurements of OxLDL-E06, apoB-100 immune complexes (apoB-IC), OxLDL autoantibodies, and Lp(a) at baseline and after 16 weeks.
  • Analysis of OxPL and apoB-100 levels, both total and normalized per apoB-100 particle.

Main Results

  • Atorvastatin significantly reduced total apoB-100, total OxPL, and apoB-IC levels (IgG and IgM) compared to placebo.
  • Normalized OxPL per apoB-100 particle (OxPL/apoB) and Lp(a) levels increased with atorvastatin treatment.
  • A strong positive correlation was observed between OxPL/apoB and Lp(a), supporting Lp(a)'s role in binding OxPL.

Conclusions

  • Atorvastatin treatment decreases total OxPL on apoB-100 particles but enriches OxPL on a smaller apoB-100 pool.
  • Increased Lp(a) levels correlate with OxPL enrichment, suggesting Lp(a) binding.
  • These findings support the hypothesis that atorvastatin promotes the clearance of proinflammatory OxPL, potentially reducing ischemic events in ACS patients.

Related Experiment Videos

Contact us if these videos are not relevant.

Related Concept Videos